Anti-leukocyte function-1 antibody treatment prevents the rejection of intraocular regressor tumors and their metastases

Xiao Yan Li, Elizabeth Mayhew, Jerry Y. Niederkorn

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The role of the cell adhesion molecules, LFA-1 and ICAM-1, in intraocular tumor rejection was examined using four different syngeneic intraocular regressor tumors and four different inbred mouse strains. All four tumors undergo T cell-dependent immune rejection in the syngeneic host. Two of the tumors, D5.1G4 melanoma and P91 mastocytoma, undergo rejection by a cytotoxic T lymphocyte-like immune process. The other two tumors, UV5C25 fibrosarcoma and 124E2 melanoma, are rejected by a process that appears to be mediated by delayed-type hypersensitivity. Systemic administration of anti-LFA-1 prevented the rejection of all four categories of tumors. By contrast, similar in vivo treatment with anti-ICAM-1 antibody did not inhibit tumor rejection. The effect of anti-LFA-1 and anti-ICAM-1 antibody treatment on the rejection of metastases arising from intraocular P91 tumors was also examined and found to be highly dependent upon normal LFA-1 function since antibody treatment with anti-LFA-1 prevented the rejection of metastases. Treatment with anti-ICAM-1 antibody alone had no appreciable effect on the rejection of metastases. The results from this study indicate that the expression and function of LFA-1 is crucial for the generation of immune responses to tumor antigens originating within the eye and the expression of tumor immunity within the eye and at distant sites.

Original languageEnglish (US)
Pages (from-to)719-726
Number of pages8
JournalCurrent Eye Research
Volume14
Issue number8
DOIs
StatePublished - 1995

Fingerprint

Lymphocyte Function-Associated Antigen-1
Leukocytes
Neoplasm Metastasis
Antibodies
Intercellular Adhesion Molecule-1
Neoplasms
Melanoma
Mastocytoma
Inbred Strains Mice
Fibrosarcoma
Delayed Hypersensitivity
Cell Adhesion Molecules
Cytotoxic T-Lymphocytes
Neoplasm Antigens
Immunity
T-Lymphocytes

Keywords

  • Cell adhesion molecules
  • Intercellular adhesion molecule-1 (ICAM-1)
  • Leukocyte function antigen-1 (LFA-1)
  • Mouse
  • T cells
  • Tumor metastasis

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Anti-leukocyte function-1 antibody treatment prevents the rejection of intraocular regressor tumors and their metastases. / Li, Xiao Yan; Mayhew, Elizabeth; Niederkorn, Jerry Y.

In: Current Eye Research, Vol. 14, No. 8, 1995, p. 719-726.

Research output: Contribution to journalArticle

@article{8d6cb7781a1f41a4abfa6f3f380d4388,
title = "Anti-leukocyte function-1 antibody treatment prevents the rejection of intraocular regressor tumors and their metastases",
abstract = "The role of the cell adhesion molecules, LFA-1 and ICAM-1, in intraocular tumor rejection was examined using four different syngeneic intraocular regressor tumors and four different inbred mouse strains. All four tumors undergo T cell-dependent immune rejection in the syngeneic host. Two of the tumors, D5.1G4 melanoma and P91 mastocytoma, undergo rejection by a cytotoxic T lymphocyte-like immune process. The other two tumors, UV5C25 fibrosarcoma and 124E2 melanoma, are rejected by a process that appears to be mediated by delayed-type hypersensitivity. Systemic administration of anti-LFA-1 prevented the rejection of all four categories of tumors. By contrast, similar in vivo treatment with anti-ICAM-1 antibody did not inhibit tumor rejection. The effect of anti-LFA-1 and anti-ICAM-1 antibody treatment on the rejection of metastases arising from intraocular P91 tumors was also examined and found to be highly dependent upon normal LFA-1 function since antibody treatment with anti-LFA-1 prevented the rejection of metastases. Treatment with anti-ICAM-1 antibody alone had no appreciable effect on the rejection of metastases. The results from this study indicate that the expression and function of LFA-1 is crucial for the generation of immune responses to tumor antigens originating within the eye and the expression of tumor immunity within the eye and at distant sites.",
keywords = "Cell adhesion molecules, Intercellular adhesion molecule-1 (ICAM-1), Leukocyte function antigen-1 (LFA-1), Mouse, T cells, Tumor metastasis",
author = "Li, {Xiao Yan} and Elizabeth Mayhew and Niederkorn, {Jerry Y.}",
year = "1995",
doi = "10.3109/02713689508998500",
language = "English (US)",
volume = "14",
pages = "719--726",
journal = "Current Eye Research",
issn = "0271-3683",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Anti-leukocyte function-1 antibody treatment prevents the rejection of intraocular regressor tumors and their metastases

AU - Li, Xiao Yan

AU - Mayhew, Elizabeth

AU - Niederkorn, Jerry Y.

PY - 1995

Y1 - 1995

N2 - The role of the cell adhesion molecules, LFA-1 and ICAM-1, in intraocular tumor rejection was examined using four different syngeneic intraocular regressor tumors and four different inbred mouse strains. All four tumors undergo T cell-dependent immune rejection in the syngeneic host. Two of the tumors, D5.1G4 melanoma and P91 mastocytoma, undergo rejection by a cytotoxic T lymphocyte-like immune process. The other two tumors, UV5C25 fibrosarcoma and 124E2 melanoma, are rejected by a process that appears to be mediated by delayed-type hypersensitivity. Systemic administration of anti-LFA-1 prevented the rejection of all four categories of tumors. By contrast, similar in vivo treatment with anti-ICAM-1 antibody did not inhibit tumor rejection. The effect of anti-LFA-1 and anti-ICAM-1 antibody treatment on the rejection of metastases arising from intraocular P91 tumors was also examined and found to be highly dependent upon normal LFA-1 function since antibody treatment with anti-LFA-1 prevented the rejection of metastases. Treatment with anti-ICAM-1 antibody alone had no appreciable effect on the rejection of metastases. The results from this study indicate that the expression and function of LFA-1 is crucial for the generation of immune responses to tumor antigens originating within the eye and the expression of tumor immunity within the eye and at distant sites.

AB - The role of the cell adhesion molecules, LFA-1 and ICAM-1, in intraocular tumor rejection was examined using four different syngeneic intraocular regressor tumors and four different inbred mouse strains. All four tumors undergo T cell-dependent immune rejection in the syngeneic host. Two of the tumors, D5.1G4 melanoma and P91 mastocytoma, undergo rejection by a cytotoxic T lymphocyte-like immune process. The other two tumors, UV5C25 fibrosarcoma and 124E2 melanoma, are rejected by a process that appears to be mediated by delayed-type hypersensitivity. Systemic administration of anti-LFA-1 prevented the rejection of all four categories of tumors. By contrast, similar in vivo treatment with anti-ICAM-1 antibody did not inhibit tumor rejection. The effect of anti-LFA-1 and anti-ICAM-1 antibody treatment on the rejection of metastases arising from intraocular P91 tumors was also examined and found to be highly dependent upon normal LFA-1 function since antibody treatment with anti-LFA-1 prevented the rejection of metastases. Treatment with anti-ICAM-1 antibody alone had no appreciable effect on the rejection of metastases. The results from this study indicate that the expression and function of LFA-1 is crucial for the generation of immune responses to tumor antigens originating within the eye and the expression of tumor immunity within the eye and at distant sites.

KW - Cell adhesion molecules

KW - Intercellular adhesion molecule-1 (ICAM-1)

KW - Leukocyte function antigen-1 (LFA-1)

KW - Mouse

KW - T cells

KW - Tumor metastasis

UR - http://www.scopus.com/inward/record.url?scp=0029159980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029159980&partnerID=8YFLogxK

U2 - 10.3109/02713689508998500

DO - 10.3109/02713689508998500

M3 - Article

C2 - 8529408

AN - SCOPUS:0029159980

VL - 14

SP - 719

EP - 726

JO - Current Eye Research

JF - Current Eye Research

SN - 0271-3683

IS - 8

ER -